Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 8/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396051 | 0.86 | LMNA (0.62) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL20734878 | 0.86 | LMNA (0.55) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL17278260 | 0.86 | LMNA (0.55) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL26911561 | 0.85 | LMNA (0.56) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL26911565 | 0.84 | KDM4E (0.57) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL5479694 | 0.84 | LMNA (0.67) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL15760447 | 0.84 | LMNA (0.59) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL11398926 | 0.83 | LMNA (0.57) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL18913377 | 0.82 | LMNA (0.54) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL11399951 | 0.81 | LMNA (0.64) | LMNAKMT2AKDM4ECYP1A2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | RNMT, NTPCR, SYNCRIP | LMNA 440/4885KMT2A 980/4885KDM4E 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.